Storia in 1 fonti

Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3

Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's fadeucravacitinib hits Phase 3 endpoint in psoriasis.

Raccontata da

endpoints.news

Timeline cronologica

martedì 28 luglio 2026·endpoints.news
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's fadeucravacitinib hits Phase 3 endpoint in psoriasis.